Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.
1. A pharmaceutical composition comprising, as active ingredients, a fusion protein dimer comprising a CD80 fragment and an IL-2 variant; and an anticancer agent,
wherein the CD80 fragment is an extracellular domain of CD80 protein;
wherein the IL-2 variant comprises the amino acid sequence of SEQ ID NO: 10 with substitutions of R38A and F42A;
wherein the fusion protein has the following structural formula (I) or (II):
N′-X-[linker(1)] n -Fc domain-[linker(2)] m -Y-C′ (I)
N′-Y-[linker(1)] n -Fc domain-[linker(2)] m -X-C′ (II)
in the structural formulas (I) and (II),
N′ is the N-terminus of the fusion protein,
C′ is the C-terminus of the fusion protein,
X is the extracellular domain of CD80 protein,
Y is the IL-2 variant comprising the amino acid sequence of SEQ ID NO: 10 with substitutions of R38A and F42A,
the linkers (1) and (2) are peptide linkers, and
n and m are each independently 0 or 1,
and wherein the anticancer agent is selected form the group consisting of an anti-PD-1 (programmed cell death protein 1) antibody, an anti-PD-L1 (programmed cell death ligand 1) antibody, an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) antibody, a VEGFR (vascular endothelial growth factor receptor) inhibitor, an EGFR (epidermal growth factor receptor) inhibitor, a PARP (poly (ADP-ribose) polymerase) inhibitor, a DNA methyltransferase inhibitor, a TGF-β (Transforming growth factor beta) receptor inhibitor, a CDK4/6 (cyclin-dependent kinase 4 and 6) inhibitor, a STING (stimulator of interferon genes) agonist, an alkylating agent, a microtubule inhibitor, an antimetabolite, a topoisomerase inhibitor, and combinations thereof.
2. The pharmaceutical composition of claim 1 , wherein the VEGFR inhibitor is selected from the group consisting of Axitinib, Lenvatinib, Bevacizumab, Ramucirumab and Aflibercept.
3. The pharmaceutical composition of claim 1 , wherein the EGFR inhibitor is selected from the group consisting of Cetuximab, Trastuzumab, Pertuzumab, Gefitinib, Elotinib and Panitumumab.
4. The pharmaceutical composition of claim 1 , wherein the PARP inhibitor is selected from the group consisting of Olaparib, Talazoparib, Niraparib and Rucaparib.
5. The pharmaceutical composition of claim 1 , wherein the DNA methyltransferase inhibitor is selected from the group consisting of Guadecitabine, Decitabine and Azacitidine.
6. The pharmaceutical composition of claim 1 , wherein the TGF-β receptor inhibitor is selected from the group consisting of Galunisertib and Vactosertib.
7. The pharmaceutical composition of claim 1 , wherein the CDK4/6 inhibitor is selected from the group consisting of Ribociclib, Abemaciclib and Palbociclib.
8. The pharmaceutical composition of claim 1 , wherein the STING agonist is selected from the group consisting of DMXAA (5,6-dimethylxanthenone-4-acetic acid), a CDN (cyclic dinucleotide) and SB11285.
9. The pharmaceutical composition of claim 1 , wherein the alkylating agent is selected from the group consisting of Cisplatin, Mechlorethamine, Cyclophosphamaide, Ifosfamide, Melphalan, Chlorambucil, Thiotepa, Altretamine, Procarbazine, Busulfan, Streptozocin, Carmustine, Iomustine, Dacabazine, Carboplatin and Oxaliplatin.
10. The pharmaceutical composition of claim 1 , wherein the microtubule inhibitor is selected from the group consisting of Docetaxel, Velban, Oncovin and Navelbine.
11. The pharmaceutical composition of claim 1 , wherein the antimetabolite is selected from the group consisting of Pemetrexed, Fluorouracil, Cytarabine, Fludarabine, Methotrexate, Mercaptopurine, Gemcitabine and Capecitabine.